Skip to main content
Premium Trial:

Request an Annual Quote

Matthew Pando, John Jaskowiak, Philippe Rousseau, Bruno Tocque, Douglas Amorese

Premium
ExonHit Therapeutics said last week that Matthew Pando and John Jaskowiak will join the company’s management board, and Philippe Rousseau will become president of the board until the company appoints a new CEO. Rousseau has been chief financial officer at ExonHit since 2002 and has been a member of its management board since 2004. The firm’s previous CEO and co-founder Bruno Tocque will remain with ExonHit in a consulting position.
 
Jaskowiak started with the company in 2006, and was recently appointed head of Molecular Diagnostics and Genomic Services. Pando came to the company in 2002, and recently was named head of its Therapeutics Unit.
 

 
Douglas Amorese has been named vice president of research and development at NuGen Technologies, the firm said this week.  
 
Amorese was most recently director of R&D in Agilent Technologies’ genomics group. He has also held positions at Life Technologies and DuPont.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.